Studying the Effect of Montelukast in the Treatment of Dysmenorrhea: A single-Blind, Placebo-controlled Trial
Background: In the field of gynecology, studies have found high levels of leukotriene in the endometrium and uterine smooth muscles of patients with dysmenorrheal and menstrual pain.Aim: to evaluate the effectiveness of montelukast in relieving the symptoms of dysmenorrhea. Patients and methods: A randomized, single-blind, prospective, placebo-controlled study was designed. Seventy patients suffering from dysmenorrhea complete this study, divided randomly into two groups: montelukast group (34 patients) and placebo group (36 patients).Values before and after treatment were compared over two menstrual cycles, using visual analog scale (VAS) score and NSAID usage per menstrual cycle. Results: Post-treatment VAS score and NSAID usage decreased significantly in both montelukast and placebo group, compared to their pre-treatment values (P<0.05). The mean decreases in VAS score and NSAID usage were more in the montelukast group than in the placebo group, but the differences were not statistically significant (p>0.05). The ratio of the highly effective cases, for both VAS score and NSAID usage, was significantly higher in the montelukast group than placebo group (P<0.05). Means of VAS score and NSAID usage didn't change in all of endometriosis patients after administration of montelukast or placebo therapy. Conclusions: For some women, montelukast may be effective in relieving symptoms of primary dysmenorrhea. It's safe and has no serious adverse effects. Thus, it can be considered as a good option for treatment of primary dysmenorrhea before starting with hormonal therapy.